Pages that link to "Item:Q5227806"
From MaRDI portal
The following pages link to Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping (Q5227806):
Displaying 14 items.
- Two-stage design for phase II oncology trials with relaxed futility stopping (Q1747566) (← links)
- Correlation coefficients for a study with repeated measures (Q2176050) (← links)
- Optimal two-stage group-sequential designs (Q2475735) (← links)
- Optimal adaptive two-stage designs for phase II cancer clinical trials (Q2858002) (← links)
- Curtailment in single-arm two-stage phase II oncology trials (Q2912001) (← links)
- Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations (Q3094217) (← links)
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials (Q3442979) (← links)
- Two-Stage Experimental Designs: Early Stopping with a Negative Result (Q4843991) (← links)
- Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm (Q5076974) (← links)
- Stopping for efficacy in single-arm phase II clinical trials (Q5093024) (← links)
- Conservative confidence intervals for the intraclass correlation coefficient for clustered binary data (Q5093029) (← links)
- An Adaptive Two‐stage Design with Treatment Selection Using the Conditional Error Function Approach (Q5122858) (← links)
- A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies (Q6076520) (← links)
- Comments on ``Exact inference for the random-effect model for meta-analyses with rare events'' (Q6627568) (← links)
